HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells

Current HIV Research

Volumn 9, Issue 4, 2011, Pages 202-208

  Lin, Shiguan ^a   Zhang, Yuhao ^a   Ying, Hao ^a   Zhu, Huanzhang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

AIDS; Apicidin; Histone acetylation; Histone deacetylase inhibitors; Human immunodeficiency virus type 1; Latent reservoirs

Indexed keywords

APICIDIN; HISTONE; HISTONE H3; HISTONE H4; TRICHOSTATIN A;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NUCLEOSOME; PROTEIN MODIFICATION; VIRUS GENE; VIRUS LATENCY; VIRUS REACTIVATION;

EID: 79960023594     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211796320333     Document Type: Article

References (44)

1. Persaud D, Zhou Y, Siliciano JM, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: No easy answers. J Virol 2003; 77: 1659-1665.
2. Davey RT, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 15109-151914.
3. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 13193-13197.
4. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1999; 5: 512-517.
5. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
6. Zhang LQ, Chung C, Hu BS, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000; 106: 839-845.
7. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replicationcompetent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-1295.
8. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine 2007; 39: 63-74.
9. Han YF, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007; 5: 95-106.
10. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009; 6: 111.
11. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The Challenge of Finding a Cure for HIV Infection. Science 2009; 323: 1304-1307.
12. Savarino A, Mai A, Norelli S, et al. Shock and kill effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009; 6.
13. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7: 798-812.
14. Verdin E, Paras P, Vanlint C. Chromatin Disruption In The Promoter Of Human-Immunodeficiency-Virus Type-1 During Transcriptional Activation. Embo J 1993; 12: 3249-3259.
15. Quivy V, De Walque S, Van Lint C. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies. Subcell Biochem 2007; 41: 371-896.
16. Coull JJ, Romerio F, Sun JM, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000; 74: 6790-6799.
17. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappa B p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. Embo J 2006; 25: 139-149.
18. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. Embo J 2007; 26: 4985-4995.
19. Imai K, Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem 2006; 281: 12495-12505.
20. Jiang GC, Espeseth A, Hazuda DJ, Margolis DM. C-Myc and sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007; 81: 10914-10923.
21. Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. Embo J 2001; 20: 1726-1738.
22. VanLint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. Embo J 1996; 15: 1112-1120.
23. Ying H, Zhang YH, Lin SG, Han YF, Zhu HZ. Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int J Mol Med 2010; 26: 265-2672.
24. Yin H, Zhang Y, Zhou X, Zhu H. Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol Biol Rep: 1-8.
25. Contreras X, Schweneker M, Chen CS et al. Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells. J Biol Chem 2009; 284: 6782-6789.
26. DarkinRattray SJ, Gurnett AM, Myers RW, et al. Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 13143-13147.
27. Jones P, Altamura S, Chakravarty PK, et al. A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg Med Chem Lett 2006; 16: 5948-5952.
28. Han JW, Ahn SH, Park SH, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21(WAF1/Cip1) and gelsolin. CANCER RESEARCH 2000; 60: 6068-6074.
29. Ahn MY, Chung HY, Choi WS, Lee BM, Yoon S, Kim HS. Antitumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4. Int J Oncol 2010; 36: 125-131.
30. Kwon HK, Ahn SH, Park SH, et al. A Novel gamma-Lactam- Based Histone Deacetylase Inhibitor Potently Inhibits the Growth of Human Breast and Renal Cancer Cells. Biol Pharm Bull 2009; 32: 1723-1727.
31. Reuse S, Calao M, Kabeya K, et al. Synergistic Activation of HIV- 1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection. PLoS ONE 2009; 4.
32. Blazkova J, Trejbalova K, Gondois-Rey F, et al. CpG Methylation Controls Reactivation of HIV from Latency. PLoS Pathogens 2009; 5.
33. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J 2003; 22: 1868-1877.
34. Isobe I, Michikawa M, Yanagisawa K. Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid beta-protein and chloroquine in cultured rat astrocytes. Neurosci Lett 1999; 266: 129-132.
35. Tominaga H, Ishiyama M, Ohseto F, et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun 1999; 36: 47-50.
36. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid. AIDS Res Hum Retroviruses 2009; 25: 207-212.
37. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18: 1101-1108.
38. Prins JM, Jurriaans S, van Praag RME, et al. Immune-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999; 13: 2405-2410.
39. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26: 1351-1356.
40. Davis R, Peters DH, McTavish D. Valproic Acid - A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-372.
41. De Ruijter AJM, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737-749.
42. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection. Nature 1997; 387: 183-188.
43. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23: 1799-1806.
44. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. Epigenetic Regulation of HIV-1 Latency by Cytosine Methylation. PLoS Pathogens 2009; 5.